AstraZeneca ((AZN)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
AstraZeneca is conducting a pivotal phase III study titled ‘A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination With Carboplatin Plus Pemetrexed Versus Platinum Plus Pemetrexed or Nivolumab Plus Ipilimumab in Participants With Unresectable Pleural Mesothelioma (eVOLVE-Meso).’ The study aims to evaluate the efficacy and safety of Volrustomig combined with Carboplatin and Pemetrexed compared to standard treatments in patients with unresectable pleural mesothelioma.
The intervention being tested is Volrustomig (MEDI5752), an experimental drug administered with Carboplatin and Pemetrexed, intended to treat unresectable pleural mesothelioma by potentially improving patient outcomes compared to existing therapies.
This randomized, open-label trial involves approximately 825 participants who will receive either the experimental combination or the investigator’s choice of standard care. The study uses a parallel intervention model with single masking for outcomes assessors, focusing primarily on treatment efficacy.
The study began on October 4, 2023, with an estimated primary completion date in 2025 and the last update submitted on August 27, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
The update on this study could influence AstraZeneca’s stock performance positively, as successful outcomes may enhance their oncology portfolio. Investors should also consider the competitive landscape, as other companies are developing treatments for similar conditions.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.